Hyarulonic acid derivative based three dimensional matrix
Use of a biological material containing: e) a three-dimensional matrix based on a hyaluronic acid derivative and optionally f) chondrocytes and/or mesenchymal cells partially or completely differentiated towards chondrocytes for the preparation of a graft to be surgically implanted into a joint cartilage damaged by or to be protected against a degenerative and/or inflammatory pathology.
1. A surgical method for recovering or protecting a joint cartilage from a degenerative and/or inflammatory pathology, associated with the production of IL-1, selected from osteoarthritis, psoriatic and rheumatoid arthritis, said method comprising the step of implanting into a subject in need thereof a graft consisting essentially of a biological material containing:
a) a three-dimensional matrix based on a hyaluronic acid derivative in the form of a non-woven tissue and selected from the class of hyaluronic acid benzyl esters having a percentage of esterification ranging from 75 to 100%; and optionally
b) chondrocytes and/or mesenchymal cells partially or completely differentiated towards chondrocytes.
2. The method according to claim 1 , wherein the biological material contains said cells (b), said graft being an in vitro cartilage tissue to be surgically implanted in vivo inside the joint capsule wherein the extracellular cartilage matrix is degraded by said pathology.
3. The method according to claim 2 , wherein said graft further consists essentially of the extracellular matrix produced by said b) chondrocytes and/or mesenchymal cells partially or completely differentiated towards chondrocytes, said extracellular matrix being both within said graft and inside the joint cartilage after the graft implantation.
4. The method according to claim 1 , wherein said graft is surgically implanted at the beginning of the process of degradation of the extracellular matrix of the cartilage.
5. The method according to claim 1 , wherein said graft is surgically implanted at later stages of said pathology.
6. The method according to claim 1 , wherein the average molecular weight of hyaluronic acid in the hyaluronic acid derivative range between 1×10 5 Da and 1×10 6 Da.
7. The method according to claim 6 , wherein the average molecular weight of hyaluronic acid range between 200,000 and 750,000 Da.
8. The method according to claim 1 , wherein the hvaluronic acid derivative has a percentage of esterification ranging from 75 to 100%, and the remaining percentage of unesterified hyaluronic acid is salified with an organic or inorganic base.
9. The method according to claim 8 , wherein said base is sodium hydroxide.